The Technical AnalystExchange: TWO Sector: Healthcare Industry: Biotechnology
Savior Lifetec Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.06% TWD21.35
America/New_York / 7 mai 2024 @ 01:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6 776.47 mill |
| EPS: | 0.0900 |
| P/E: | 237.22 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 317.40 mill |
| Avg Daily Volume: | 1.976 mill |
| RATING 2024-05-07 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 6.82x |
| Company: PE 237.22 | sector: PE 34.77 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 4.09x |
| Company: PE 237.22 | industry: PE 58.06 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
TWD7.88 (-63.09%) TWD-13.47 |
| Date: 2024-05-07 |
| Expected Trading Range (DAY) |
|---|
|
TWD 20.77 - 21.93 ( +/- 2.72%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | TWD21.35 (-2.06% ) |
| Volume | 2.14 mill |
| Avg. Vol. | 1.976 mill |
| % of Avg. Vol | 108.34 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 4167.TWO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
4167.TWO
Savior Lifetec Corporation, a specialty injectable company, produces and supplies sterile APIs and finished dosage formulations. The company offers imipenem and cilastatin sodium, an antibacterial agent for intravenous infusion; and meropenem, a beta-lactamase resistant carbapenem antibiotic for parenteral administration. It also provides ertapenem, a form of carbapenem for use on gram-negative and gram-positive anaerobes and aerobic. The company's pipeline products include SLC-006 for prostate cancer endometriosis uterine leiomyoma; and sterile paliperidone palmitate API for the treatment of schizophrenia. Savior Lifetec Corporation was founded in 2004 and is headquartered in Miaoli County, Taiwan.